BioXell Starts Elocalcitol Phase IIa Trial

Italy’s BioXell has enrolled the first patient in its Phase IIa trial of Elocalcitol, a treatment for male infertility.

The 234-patient, randomized, double-blind, placebo-controlled, parallel-group trial is designed to test the ability of the drug to improve sperm quality in infertile male patients. Elocalcitol will be tested at 75- and 150-microgram doses versus placebo for an effect on various sperm parameters.

Results are expected by the end of 2008, BioXell said.